Vericel price target raised to $47.40 from $42.40 at Ladenburg

Ladenburg raised the firm’s price target on Vericel to $47.40 from $42.40 and keeps a Buy rating on the shares post the Q4 report. The firm says MACI growth is driven by strong business fundamentals, the continuous expansion of the surgeon base, increased biopsies, and consistent conversion rates. Vericel continues to demonstrate strong growth as a result of greater market penetration, sales representative efficiency, and the addition of NexoBrid as a complement within the burn franchise, the analyst tells investors in a research note.